Akiyama S, Fukuda S, Steinberg JM, Suzuki H, Tsuchiya K. Characteristics of inflammatory bowel diseases in patients with concurrent immune-mediated inflammatory diseases. World J Gastroenterol 2022; 28(25): 2843-2853 [PMID: 35978883 DOI: 10.3748/wjg.v28.i25.2843]
Corresponding Author of This Article
Shintaro Akiyama, MD, MSc, PhD, Lecturer, Department of Gastroenterology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Ibaraki, Japan. akiyama@md.tsukuba.ac.jp
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Shintaro Akiyama, Soma Fukuda, Hideo Suzuki, Kiichiro Tsuchiya, Department of Gastroenterology, University of Tsukuba, Tsukuba 305-8575, Ibaraki, Japan
Joshua M Steinberg, Inflammatory Bowel Disease, Gastroenterology of the Rockies, Denver, CO 80218, United States
Author contributions: Akiyama S designed the research; Akiyama S and Fukuda S performed the research and analyzed the data; Akiyama S, Fukuda S, Steinberg JM, Suzuki H, and Tsuchiya K wrote the paper.
Conflict-of-interest statement: Akiyama S, Fukuda S, and Suzuki H have no relevant disclosures; Steinberg JM was on Advisory Board for Pfizer; Tsuchiya K has received grant supports from Takeda Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharmaceutical Corp., and Hitachi Ltd.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Shintaro Akiyama, MD, MSc, PhD, Lecturer, Department of Gastroenterology, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8575, Ibaraki, Japan. akiyama@md.tsukuba.ac.jp
Received: January 8, 2022 Peer-review started: January 8, 2022 First decision: March 9, 2022 Revised: March 10, 2022 Accepted: May 28, 2022 Article in press: May 28, 2022 Published online: July 7, 2022 Processing time: 176 Days and 19.6 Hours
Abstract
Patients with inflammatory bowel disease (IBD) are more likely to have concurrent immune-mediated inflammatory diseases (IMIDs) than those without IBD. IMIDs have been observed to alter the phenotype and outcomes of IBD in recent studies. Several studies have found that IBD patients with concurrent IMIDs may have more extensive or severe disease phenotypes, and are considered to be at increased risk of requiring biologics and IBD-related surgeries, suggesting that having multiple IMIDs is a poor prognostic factor for IBD. Furthermore, IBD patients with primary sclerosing cholangitis and Takayasu arteritis are reported to have unique endoscopic phenotypes, suggesting concurrent IMIDs can influence IBD phenotype with specific intestinal inflammatory distributions. In this review, we discuss the pathogenesis, disease phenotypes, and clinical outcomes in IBD patients with concomitant IMIDs.
Core Tip: Patients with inflammatory bowel disease (IBD) are more likely to acquire other immune-mediated inflammatory diseases (IMIDs). IBD patients with concurrent IMIDs were more likely to require biologics and IBD-related surgeries than non-IBD patients due to extensive disease phenotypes according to recent studies. As a result, when treating IBD patients, we must be aware of the concurrence of other IMIDs and understand its pathogenesis to select biologic and small molecule therapies that treat multiple concomitant diseases.
